The Robert A Welch Foundation Catalyst for Discovery Program is intended to accelerate progress in fundamental chemistry research by supporting research teams in Texas aimed at significant problems at the leading edge of chemistry. Annually, up to 2 grants of $5,000,000 each will be awarded to highly meritorious proposals. The level of support is calibrated to reduce barriers to discovery and provide flexibility in the manner of experimentation with minimal administrative burden. Catalyst for Discovery Program Grants are intended to support fundamental chemical research at institutions in Texas aimed at solving significant problems for the benefit of humankind.

UTMB Internal RFA 2026

The American Diabetes Association's Pathway to Stop Diabetes provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to groundbreaking discoveries in diabetes prevention, management, and cures. The program aims to build a pathway to tackle the toughest questions in diabetes by driving research innovations through 1:1 mentorship and building a brain trust in diabetes. The ideal applicant will propose innovative research that will be an important step toward the eventual goal of improving the lives of people at risk of or living with diabetes.

The Initiator Award is designed to support the transition of scientists from mentored training to independent research.
The Accelerator Award is designed to support promising early career researchers in the beginning stages of establishing successful, sustainable diabetes research programs.

2026 Internal RFA

The purpose of the GCC John S Dunn Foundation Collaborative Research Award Program is to foster new, exemplary inter-disciplinary and inter-institutional engagement in the quantitative biomedical sciences by providing research seed grants. The goal of this program is to fund new projects with high potential for future competitive research funding within 2.5 years of project start and a "best case scenario" plan for transitioning to clinical studies within 5 years. 

Funds will be awarded to NEW collaborative teams in which the PI and co-PI are from different GCC member institutions: Baylor College of Medicine, Rice University, University of Houston, UT Health Science Center at Houston, UTMB, UT MD Anderson Cancer Center, The Texas A&M (TAMU) Institute of Biosciences and Technology (IBT) in Houston, and Houston Methodist Research Institute. 

2026 UTMB Internal RFA

2026 Sponsor RFA